reports
1 director bought
A director at VBI Vaccines Inc bought 10,000,000 shares at 0.500USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
VBI Vaccines to Present at the H.C. Wainwright 21st Annual Global Inve...
VBI Vaccines to Present at the H.C. Wainwright 21st Annual Global Investment Conference CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Jeff Baxter, President and CEO, will present at the H.C. Wainwright 21st Annual Global Investment Conference in New York City on Tuesday, September 10, 2019, at 8:20 AM ET. - Event: H.C. Wainwright 21st Annual Global Investment Conference - Date: Tuesday, S...
VBI Vaccines Announces Second Quarter 2019 Financial Results and Provi...
VBI Vaccines Announces Second Quarter 2019 Financial Results and Provides Corporate Update Positive top-line data from PROTECT Phase 3 for Sci-B-Vac®, trivalent hepatitis B vaccine, announced June 2019 – top-line data from second Phase 3 study, CONSTANT, expected around year-end 2019ASCO presentation illustrated encouraging data from Part A of the ongoing Phase 1/2a study of VBI-1901 in recurrent glioblastoma (GBM) patients – first patient in Part B of the study was dosed in July 2019Therapeutic hepatitis B program remains on track for expected initiation of enrollment in a Phase 2 study in...
VBI Vaccines to Present at the Canaccord Genuity 39th Annual Growth Co...
VBI Vaccines to Present at the Canaccord Genuity 39th Annual Growth Conference CAMBRIDGE, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Jeff Baxter, President and CEO, will present at the Canaccord Genuity 39th Annual Growth Conference in Boston, MA, on Thursday, August 8, 2019, at 1:30 PM ET. - Event: Canaccord Genuity 39th Annual Growth Conference - Date: Thursday, August 8, 2019 - Time: 1:30 ...
VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Part B...
VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Part B of Ongoing Phase 1/2a Study of VBI-1901 — Part B of the study, a subsequent extension of the optimal dose from Part A, to enroll 10 first-recurrent GBM patients— Initial immunologic data from Part B expected around year-end 2019— Expanded immunologic data and tumor and clinical responses expected H1 2020 CAMBRIDGE, Mass., July 29, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, to...
VBI Vaccines Added to Russell 2000® and Russell 3000® Indexes
VBI Vaccines Added to Russell 2000® and Russell 3000® Indexes CAMBRIDGE, Mass., July 01, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, announced today that it has been added to the Russell 2000® and the Russell 3000® Indexes following the annual reconstitution, effective after the US market opens on Monday, July 1, 2019. Annual reconstitution of the Russell US Indexes captures the 4,000 largest US stocks as of May 10, ranking them by total market c...
VBI Vaccines to Present at the BMO Capital Markets 2019 Prescriptions ...
VBI Vaccines to Present at the BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference CAMBRIDGE, Mass., June 20, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Jeff Baxter, President and CEO, will participate in an analyst-led fireside chat at the BMO Capital Markets Prescriptions for Success Healthcare Conference on Tuesday, June 25, 2019, at 11:20 AM ET in New York City. - Event: BMO Capital Markets 2019 ...
VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivot...
VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivotal Phase 3 Study of Sci-B-Vac® Both co-primary endpoints successfully met – including non-inferiority in all adults age ≥18 years, and superiority in adults age ≥ 45 yearsSeroprotection rates four weeks post-3rd vaccination of Sci-B-Vac® vs. Engerix-B® were statistically significantly higher in key subgroup analyses of adults age ≥ 18 yearsNo safety signals observed – safety and tolerability consistent with known profile of the vaccineWith positive PROTECT data, pending successful completion of CONSTANT study, submissions...
VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase ...
VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac® CAMBRIDGE, Mass., June 16, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, will host a conference call and webcast tomorrow morning, June 17, 2019, at 8:00 AM ET. Management looks forward to reviewing top-line data from PROTECT, one of two pivotal Phase 3 studies for Sci-B-Vac®, the company’s trivalent hepatitis B vaccine. Conference Call and Webcast...
VBI Vaccines Announces Results of Annual General Meeting
VBI Vaccines Announces Results of Annual General Meeting CAMBRIDGE, Mass., June 13, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI" or the "Company"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the voting results from its annual general meeting of shareholders held on June 13, 2019 (the "Meeting"). The total number of common shares of the Company ("Common Shares") represented by shareholders ("Shareholders") present in person or represented by proxy at the Meeting was an aggrega...
VBI Vaccines Reports Data from Part A of the Ongoing Phase 1/2a Study ...
VBI Vaccines Reports Data from Part A of the Ongoing Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients at ASCO 2019 Well tolerated at all doses with no safety signalsThree patients in high dose (10 µg) cohort showed evidence of stable disease by MRI10 µg dose selected for Part B of the study, which is expected to initiate enrollment mid-year 2019 CAMBRIDGE, Mass., June 04, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, present...
VBI Vaccines Announces First Quarter 2019 Financial Results and Provid...
VBI Vaccines Announces First Quarter 2019 Financial Results and Provides Corporate Update All four lead pipeline programs progressing towards expected clinical milestones in 2019Gearing up for top-line data from the pivotal Phase 3 study of Sci-B-Vac®, VBI’s trivalent hepatitis B vaccine, expected mid-year 2019Expanded Part A data from GBM Phase 1/2a study of VBI-1901 to be presented at ASCOPart B of GBM Phase 1/2a study expected to initiate mid-year 2019Hepatitis B immunotherapeutic remains on track for initiation of Phase 2 proof-of-concept study by year-end 2019 CAMBRIDGE, Mas...
VBI Vaccines Provides Update on GBM Program and Announces Upcoming Con...
VBI Vaccines Provides Update on GBM Program and Announces Upcoming Conference Call 10mcg dose selected to advance into Part B of Phase 1/2a study of VBI-1901 in recurrent GBMExpanded data from Part A of the Phase 1/2a study of VBI-1901 selected for poster presentation at ASCOConference call and webcast Thursday, April 25, 2019 at 8:30 AM ET CAMBRIDGE, Mass., April 23, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced: Advancement into ...
VBI Vaccines Appoints Joanne Cordeiro to Board of Directors
VBI Vaccines Appoints Joanne Cordeiro to Board of Directors CAMBRIDGE, Mass., April 11, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the appointment of Joanne Cordeiro to its Board of Directors. Ms. Cordeiro most recently served as Chief Human Resources Officer and Executive Vice President of Human Resources at Shire PLC, after joining the company in 2011. “Joanne is a fantastic addition to our Board, bringing with her the experi...
VBI Vaccines Announces Late-Breaking Poster Presentation at EASL 2019
VBI Vaccines Announces Late-Breaking Poster Presentation at EASL 2019 Poster presentation to highlight data from three previously-conducted clinical studies of Sci-B-Vac®, VBI’s prophylactic Hepatitis B vaccineIn all three studies, seroprotection rates of more than 98% were achieved after two vaccinations of Sci-B-Vac® CAMBRIDGE, Mass., April 09, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”) (“the Company”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the Company’s abstra...
VBI Vaccines Announces Poster Presentation at the 7th International Co...
VBI Vaccines Announces Poster Presentation at the 7th International Congenital CMV Conference & 17th International CMV Workshop CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that David Anderson, Ph.D., Chief Scientific Officer, will present the poster, “CMV gB/pp65 eVLPs Formulated with GM-CSF as a Therapeutic Vaccine Against Recurrent Glioblastoma (GBM),” at the 7th International Congenital Cytomegalovi...
VBI Vaccines Provides Corporate Update, Outlook for 2019, and Year-End...
VBI Vaccines Provides Corporate Update, Outlook for 2019, and Year-End 2018 Financial Results Top-line data from Hepatitis B (Sci-B-Vac®) Phase 3 PROTECT trial expected mid-year 2019Encouraging early immunogenicity data from GBM Phase 1/2a supports advancing into Part B of the studyLicense and Collaboration with Brii Biosciences, to develop a functional cure for Hepatitis B, expected to initiate clinical proof of concept studies by the end of 2019 CAMBRIDGE, Mass., Feb. 25, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company dev...
VBI Vaccines Announces Third Positive DSMB Review in Phase 1/2a Study ...
VBI Vaccines Announces Third Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent GBM Patients Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of the study without modificationEnrollment is complete in the high-dose study arm of Part AExpanded immunologic data and 6-month survival data from all three dose cohorts in Part A expected in the first half of 2019 CAMBRIDGE, Mass., Feb. 07, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI” or the “Company”), a commercial-stage biopharmaceutical company developing next-generat...
VBI Vaccines Appoints Blaine McKee to Board of Directors
VBI Vaccines Appoints Blaine McKee to Board of Directors CAMBRIDGE, Mass., Jan. 16, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the appointment of Blaine McKee, Ph.D., Executive Vice President and Chief Business Officer of ImmunoGen, Inc., to the company’s Board of Directors. “Blaine is an excellent addition to our Board of Directors, bringing with him a 25-year track record of building successful biotech companies,” said Jeff Bax...
VBI Vaccines Announces Phase 2 Clinical Study Design of its Prophylact...
VBI Vaccines Announces Phase 2 Clinical Study Design of its Prophylactic CMV Vaccine Candidate CAMBRIDGE, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced its plans for a Phase 2 clinical study evaluating VBI-1501, the company’s prophylactic cytomegalovirus (CMV) vaccine candidate, following positive discussions with Health Canada. The Phase 2 study is expected to be a formal dose-ranging study designed to assess the safe...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.